Development of drugs for gastrointestinal motor disorders: translating science to clinical need
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Abstract Only a small number of new drugs have recently become available for gastrointestinal (GI) disorders. This is partly because we await outcomes of research into functional bowel disorder aetiology (e.g., role of microbiota) and of trials to control stress‐ related or painful GI symptoms (e.g., via CRF 1 receptors or β 3 adrenoceptors). Nevertheless, only the ClC‐2 channel activator lubiprostone has recently reached the clinic, joining the 5‐HT 3 antagonist alosetron and the long‐established 5‐HT 4 agonist and D 2 antagonist metoclopramide; tegaserod, a non‐selective ligand, was withdrawn. Interestingly, each has shortcomings, providing opportunities for molecules with 5‐HT 4 or motilin receptor selectivity, and for new biology via guanylate cyclase C or ghrelin receptor activation. For translation into new drugs, the molecule must have appropriate efficacy, selectivity and pharmacodynamic properties. It is argued that the compound must then be evaluated in conditions where changes in motility are known to exist, before considering more difficult symptomatic conditions such as irritable bowel syndrome (IBS) or functional dyspepsia (FD), where relationships with disordered motility are unclear. Thus, it may be better to begin studying a gastric prokinetic in diabetics requiring improved glucose control, rather than in FD. Notably, new 5‐HT 4 receptor agonists are being evaluated firstly as treatments of constipation, not IBS. New antidiarrhoeal agents should be developed similarly. Thus, progression of new drugs may require initial studies in smaller patient populations where clinical outcome is better defined. Only then can disease‐related ideas be properly tested and drugs brought forward for these disorders (with high clinical need) and then, if successful for IBS and FD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Treatment of nausea and vomiting: Gaps in our knowledge
Sanger, G. J., & Andrews, P. L. R. (2006) · Autonomic Neuroscience · doi:10.1016/j.autneu.2006.07.009 · Cited by 209
Self-citationChang, L., Chey, W. D., Harris, L., Olden, K., Surawicz, C., & Schoenfeld, P. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00459.x · Cited by 181
Cited by
The physiology, signaling, and pharmacology of dopamine receptors
Beaulieu, J.-M., & Gainetdinov, R. R. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002642 · Cited by 2,763
The enteric nervous system and neurogastroenterology
Furness, J. B. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.32 · Cited by 1,619
Tack, J., Camilleri, M., Chang, L., Chey, W. D., Galligan, J. J., Lacy, B. E., Müller‐Lissner, S., Quigley, E. M. M., Schuurkes, J., De Maeyer, J. H., et al. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2012.05011.x · Cited by 286
Irritable bowel syndrome: towards biomarker identification
Clarke, G., Quigley, E. M. M., Cryan, J. F., & Dinan, T. G. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.08.001 · Cited by 181
Dyspepsia: Organic Versus Functional
Oustamanolakis, P., & Tack, J. (2012) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e318241b335 · Cited by 146
Metadata
- Authors
- Sanger, G. J., & Alpers, D. H.
- Venue
- Neurogastroenterology & Motility
- Publisher
- Wiley
- Published
- 2008-01-31
- Volume
- 20
- Issue
- 3
- Pages
- 177-184
- ISSN
- 1350-1925 (ISSN-L)
- 1365-2982
- OpenAlex
- W2036423003
- Cited by
- 75
- References
- 2
- FWCI
- 10.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Development of drugs for gastrointestinal motor disorders: translating science to clinical need. https://app.cochat.ai/papers/10.1111/j.1365-2982.2008.01084.x
- The paper
- Sanger, G. J., & Alpers, D. H. (2008). Development of drugs for gastrointestinal motor disorders: translating science to clinical need. Neurogastroenterology & Motility. https://doi.org/10.1111/j.1365-2982.2008.01084.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.